Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice

doi:10.5246/jcps.2013.04.050

Abstract

Abstract:

Lipid nanoparticles have become attractive for its prominent properties recent years. In this paper, in vivo anti-tumor efficacy of nanostructured lipid carrier of dihydroartemisinin (DHA-NLC) were evaluated in sarcoma 180-bearing mice model through intraperitoneal (i.p.) administration. In vivo biodistribution was also investigated in Kunming mice bearing S180. Results demonstrated that the intraperitoneally injected DHA-NLC could significantly inhibit tumor growth at the dose levels of 20, 40 and 80 mg/kg, and their inhibition rates were 71.24%, 79.20% and 85.74%, respectively. The biodistribution of DHA after intraperitoneal injection of DHA-NLC in S180-bearing mice is remarkably different from the DHA solution. Therefore, DHA encapsulated in NLC does demonstrate superior anticancer effect to DHA suspension on S180-bearing mice at the same dose and displayed a dose-dependent antitumor efficacy.

Key words: Nanostructured lipid carrier, Antitumor, Sarcoma 180, Biodistribution

CLC Number:

Supporting:

Xiaoyun Zhang^*, Hua Qiao, Peng Zhao, Jingman Ni, Yanbin Shi. Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice[J]. , DOI: 10.5246/jcps.2013.04.050.

References

[1] Smets, A. Anti-cancer Drug. 1994, 5, 3-9.
[2] Langer, R. Accounts Chem Res. 2000, 33, 94-101.
[3] Van Vlerken, L.E.; Duan, Z.; Little, S.R.; Seiden, M.V.; Amiji, M.M. Mol. Pharm. 2008, 5, 516-526.
[4] Müller, R.H.; Radtke, M.; Wissing, S.A. Adv. Drug Deliv. Rev. 2002, 54, 131-155.
[5] Müller, R.H.; Keck, C.M. J. Biotechnol. 2004, 113, 151-170.
[6] Alvarez-Román, R.; Naik, A.; Kalia, Y.N.; Guy, R.H.; Fessi, H. J. Control. Release. 2004, 99, 53-62.
[7] Monika, S.K.; Wolfgang, M.; Hans-Christian, K. Adv. Drug Deliv. Rev. 2007, 59, 427-443.
[8] Paolo, B.; Stefano, G.; Aurélie, S.; Maurizio, R.; Carlo, R. Adv. Drug Deliv. Rev. 2007, 59, 454-477.
[9] Lin, X.H.; Li, X.W; Zheng, L.Q.; Yu, L.; Zhang, Q.Q.; Liu, W.C. Colloid Surf. A. Physicochem. Eng. Asp. 2007, 311, 106-111.
[10] Maeda, H.; Wu, J.; Sawa, T.; Matsumura,Y.; Hori, K. J. Control. Release. 2000, 65, 271-284.
[11] O'Neill, P.M. Nature. 2004, 430, 838-839.
[12] O'Neill, P.M.; Posner, G.H. J. Med. Chem. 2004, 47, 2945-2964.
[13] White, N.J. J. Clin. Invest. 2004, 113, 1084-1092.
[14] Monica, L.; Sara, Z.; Debora, M.; Marco, B.; Paolo, C.; Jacqueline, L.; Guy, M.; Melba, G.; Walter, R.J.; Taylor, P.O. Reprod. Toxicol. 2006, 21, 83-93.
[15] Wu, G.D.; Zhou, H.J.; Wu, X.H. Vascul. Pharmacol. 2005, 41, 205-212.
[16] Jacob, G.; Judith, H.W.; Miriam, K.; Nicholas, H.H.; Georges, E.G. Int. J. Parasitol. 2006, 36, 1427-1441.
[17] Ikuhiko, N.; Henry, L.; Narendra, P.; Singh, T.S. Int. J. Pharm. 2008, 354, 28-33.
[18] Zhang, X.Y.; Liu, J.P.; Qiao, H.; Liu, H.; Ni, J.M.; Zhang, W.L.; Shi, Y.B. Powder Technol. 2010, 197, 120-128.
[19] Zhang, X.Y.; Qiao, H.; Liu, J.P.; Dong, H.J.; Shen, C.L.; Ni, J.M.; Shi, Y.B; Xu, Y. Pharmazie. 2010, 65, 670-678.
[20] Bezerra, D.P.; Castro, F.O.; Alves, A.P.; Pessoa, C.; Moraes, M.O.; Silveira, E.R.; Lima, M.A.; Elmiro, F.J.; Alencar, N.M.; Mesquita, R.O.; Lima, M.W.; Costa-Lotufo, L.V. J. Appl. Toxicol. 2008, 28, 156-163.
[21] Zheng, M.L.; Han, B.Q.; Yang, Y.; Liu, W.S. Carbohydr. Polym. 2011, 86, 231-238.
[22] Wei, Y.Q.; Huang, M.J.; Yang, L.; Zhao, X.; Tian, L.; Lu, Y.; Shu, J.M.; Lu, C.J.; Niu, T.; Kang, B.; Mao,Y.Q.; Liu, F.; Wen, Y.J.; Lei, S.; Luo, F.; Zhou, L.Q.; Peng, F.; Jiang, Y.; Liu, J.Y.; Zhou, H.; Wang, Q.R.; He, Q.M.; Xiao, F.; Lou, Y.Y.; Xie, X.J.; Li, Q.; Wu, Y.; Ding, Z.Y.; Hu, B.; Hu, M.; Zhang, W. Proc. Natl. Acad. Sci. USA. 2001, 98, 11545-11550.
[23] Wang, J.; Chen, C.; Li, B.; Yu, H.; Zhao, Y.; Sun, J.; Li, Y.; Xing, G.; Yuan, H.; Tang, J.; Chen, Z.; Meng, H.; Gao, Y.; Ye, C.; Chai, Z.; Zhu, C.; Ma, B.; Fang, X.; Wan, L. Biochem. Pharmacol. 2006, 71, 872-881.
[24] Zhang, L.Y.; Yang, M.; Wang, Q.; Li, Y.; Guo, R.; Jiang, X.Q.; Yang, C.Z.; Liu, B.R. J. Control. Release. 2007, 119, 153-162.
[25] Morille, M.; Montier, T.; Legras, P.; Carmoy, N.; Brodin, P.; Pitard, B.; Benoit, J.P.; Passirani, C. Biomaterials. 2010, 31, 321-329.
[26] Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Pharmacol. Rev. 2001, 53, 283-318.
[27] Brigger, I.; Couvreur, P. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
[28] Iodoshima, N.; Udagawa, C.; Ando, T.; Fukuyasu, H.; Watanabe, H.; Nakabayashi, S. Int. J. Pharm. 1997, 146, 81-92.
[29] Koshkina, N.; Waldrep, J.; Knight, V. Curr. Cancer Drug Targets. 2003, 3, 251-264.
[30] Chiannilkulchai, N.; Ammoury, N.; Caillou, B.; Devissaguet, J.; Couvreur, P. Cancer Chemother. Pharmacol. 1990, 26, 122-126.
[31] Soma, C.E.; Dubernet, C.; Barratt, G.; Benita, S.; Couvreur, P. J. Control. Release. 2000, 68, 283-289.
[32] Mehnert, W.; Mader, K. Adv. Drug Deliv. Rev. 2001, 47, 165-196.
[33] Gabriëls, M.; Plaizier, V.J. Int. J. Pharm. 2004, 274, 245-260.
[34] Batty, K.T.; Davis, T.M.E.; Thu, L.T.A.; Binh, T.Q.; Anh, T.K.; Ilett, K.F. J. Chromatogr. B. 1996, 677, 345-350.